Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Malignancies, Non-small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03256721
What this trial is testing

Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
Fuzhou General Hospital 37
Testing effectiveness (Phase 2)Ended earlyNCT02109016
What this trial is testing

Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

Who this might be right for
Non-Small Cell Lung CancerSquamous Non-Small Cell Lung CancerNSCLC+6 more
Clovis Oncology, Inc. 18
Large-scale testing (Phase 3)Looking for participantsNCT06627647
What this trial is testing

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Who this might be right for
Non-squamous Non-small Cell Lung Cancer
AstraZeneca 1,160
Early research (Phase 1)Study completedNCT00603538
What this trial is testing

Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 19
Large-scale testing (Phase 3)UnknownNCT00006048
What this trial is testing

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
AstraZeneca
Large-scale testing (Phase 3)UnknownNCT02643407
What this trial is testing

Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials 488
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Early research (Phase 1)Looking for participantsNCT05877599
What this trial is testing

NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Who this might be right for
Non-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaColorectal Carcinoma+5 more
AstraZeneca 45
Testing effectiveness (Phase 2)Study completedNCT00005055
What this trial is testing

Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 39
Early research (Phase 1)UnknownNCT03628521
What this trial is testing

First-line Combination Treatment Based on Anlotinib

Who this might be right for
Lung CancerAdvanced Stage
Shanghai Chest Hospital 80
Not applicableStudy completedNCT01836133
What this trial is testing

An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 70
Testing effectiveness (Phase 2)WithdrawnNCT03164694
What this trial is testing

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Who this might be right for
Lung Cancer
Sun Yat-sen University
Testing effectiveness (Phase 2)Ended earlyNCT05715229
What this trial is testing

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Hackensack Meridian Health 5
Large-scale testing (Phase 3)Ended earlyNCT02186301
What this trial is testing

TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy

Who this might be right for
Non-Small Cell Lung Cancer
Clovis Oncology, Inc. 100
Not applicableStudy completedNCT02440854
What this trial is testing

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Boehringer Ingelheim 80
Early research (Phase 1)UnknownNCT02637531
What this trial is testing

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Who this might be right for
Advanced Solid Tumors (Part A/B/C/D)Non-small Cell Lung Cancer (Part E)Melanoma (Part E)+5 more
Infinity Pharmaceuticals, Inc. 219
Large-scale testing (Phase 3)Study completedNCT03196986
What this trial is testing

Mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Beijing Mabworks Biotech Co., Ltd. 517
Testing effectiveness (Phase 2)UnknownNCT01932229
What this trial is testing

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

Who this might be right for
NSCLC
Sheba Medical Center 20
Early research (Phase 1)Not Yet RecruitingNCT06823245
What this trial is testing

Pharmacokinetic Study of HS-10241 Tablets in Subjects with Hepatic Impairment and Normal Hepatic Function

Who this might be right for
Advanced Non-small Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07463677
What this trial is testing

Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer (NSCLC)
Sun Yat-sen University 55
Next Page